AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 92 min read$DYN

DYN Maintained by Morgan Stanley -- Price Target Lowered to $36

Morgan Stanley maintained an Overweight rating on Dyne Therapeutics (DYN) but lowered its price target from $45 to $36. The company has a market cap of $3.65B, a GF Score of 34, and significant insider selling. Analysts remain cautious due to profitability challenges and market conditions.

Original reporting
gurufocus.com
Published Sep 9, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$DYN
Bearish
medium confidence
Mentioned
$DYN
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DYNBearishLow
01

Why it matters

Analyst downgrade may trigger short-term price pressure but long-term upside remains tied to trial outcomes.

02

Market read

The price target reduction provides a modest trading signal for DYN investors.

03

What to watch

Potential pipeline advancements or partnership announcements could offset valuation concerns.

Relevance 5/10Novelty 6/10Timing: price target cut reported today

Background

Dyne Therapeutics is a clinical-stage biotech focused on neuromuscular diseases.

Company-level read

Ticker impact

$DYNBearishMedium confidence
Context

Morgan Stanley lowered Dyne Therapeutics' price target from $45 to $36, maintaining an Overweight rating.

Expected impact

Possible short-term downside as investors adjust expectations.

Evidence & confidence

The target reduction reflects concerns over profitability and market conditions, which may lead to a modest price decline.

Market effects

Sector

Biotech sector may see heightened scrutiny on profitability metrics.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The strong momentum rank (9/10) could support a rebound despite the lower target.

Key entities

  • Analyst
    Morgan Stanley

    Maintained Overweight rating while reducing price target.

  • Company
    Dyne Therapeutics

    Biotech firm with a GF Score of 34/100.

Read at source← All news

Related articles

SEP 29
$DYNHighAI 8/10

Dyne Therapeutics stock rises on positive DM1 trial results

Dyne Therapeutics (DYN) shares rose 2.1% after reporting 1-year trial data for DM1 treatment z-basivarsen. The Phase 1/2 ACHIEVE trial showed improvements in functional tests and muscle strength. The company expects topline data in Q1 2027, aiming for U.S. Accelerated Approval submission in Q3 2027. Z-basivarsen showed a favorable safety profile.

investing.com2 min
SEP 29
$DYNMedAI 9/10

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o

SEC EDGAR 8-K3 min
SEP 29
$DYNMedAI 8/10

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics (DYN) reported 12-month data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1, showing functional improvements across multiple measures. The company expects topline data from the registrational expansion cohort in Q1 2027, with a potential U.S. Accelerated Approval submission in Q3 2027. The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds.

globenewswire.com2 min
SEP 18
$DYNHighAI 9/10

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.

stocktwits.com2 min